<DOC>
	<DOCNO>NCT02582125</DOCNO>
	<brief_summary>The objective study investigate safety efficacy ONO-4538 subject stage IIIB/IV recurrent non-small cell lung cancer unsuited radical radiotherapy resistant platinum-based chemotherapeutic regimen .</brief_summary>
	<brief_title>ONO-4538 Study Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female â‰¥ 20 year age Histologically cytologically confirm nonsmall cell lung cancer Diagnosis NSCLC stage IIIB/IV unsuited radical radiotherapy accord UICCTNM classification ( 7th edition ) recurrent NSCLC Has least one measurable lesion , define RECIST guideline ( version 1.1 ) Current prior severe hypersensitivity another antibody product Multiple primary cancer</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>ONO-4538</keyword>
	<keyword>Advanced non-small cell lung cancer</keyword>
</DOC>